Edwards Lifesciences (EW) Revenue — Quarter Ended Dec 31, 2024
Revenue for the quarter increased compared to both the prior quarter and the same period last year. The growth reflects continued business momentum.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 FY
Revenue for the quarter increased compared to both the prior quarter and the same period last year. The growth reflects continued business momentum.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.4B
Revenue reported for this quarter.
Quarter-over-quarter
+2.3%
Change from the immediately preceding quarter.
Year-over-year
+9.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $1.3B | +8.9% |
| Jun 30, 2024 | $1.4B | +4.4% |
| Sep 30, 2024 | $1.4B | +11.9% |
| Dec 31, 2024 | $1.4B | +9.4% |
Revenue performance
The reported revenue growth was driven by higher sales compared to the preceding quarter and a year ago.
Quarterly comparison
The sequential increase was modest, while the year-over-year gain was more substantial.
What to watch
The company notes adequate liquidity but has remaining tax installment payments pending.